

Attachment 16 -- Questions and Answers (follow-up)

The following questions were submitted in writing by Company C. (Answers follow.)

1. With regard to Attachment 15 – Questions and Answers, Question #22: Upon review of the ~~State's Plan of Benefits document~~ 2020 Insurance Benefits Guide (available via the link - <https://www.peba.sc.gov/assets/insurancebenefitsguide.pdf>) ~~document that is referenced, on page 90~~, there is a Section on page 90 related to Exclusions. In order to continue alignment with the ~~State's Plan of Benefits document~~, can the proposed formulary provide exclusions, including insulin and other self-injectable drugs administered at home?

A: Offerors are free to propose the formulary it, in its view, is most advantageous to PEBA. Offerors are reminded that member disruption across several domains will be considered in the technical evaluation. The list of domains includes, but is not limited to, formulary disruption.

2. With regard to Attachment 15 – Questions and Answers, Question #9: Please provide additional details on how the Limited Distribution Drug list will be evaluated, including:
 - How will Limited Distribution Drugs which a PBM does not have access be utilized to compare each PBM?

A: The proportions of drugs (and specific drugs) that the Offeror does not have access to will go to the technical evaluation of each Offeror. Metrics such as number of PEBA members affected will be considered in the overall evaluation of member disruption.

- Will the NDC level Limited Distribution Drug list be used in the scoring and evaluation of each proposal?

A: The NDC level Limited Distribution Drug (LDD) list will be used to measure the number of members and prescriptions effected by Offeror's LDD lists based on PEBA claims experience. The results of these tabulations will go to the Offeror's technical score. Offerors should be reminded that Limited Distribution Drugs are included in all rebate and pricing guarantees.

- If so, please provide details of the process that will be used to score and evaluate the LDD lists provided.

A: The breadth of the Offeror's LDD list will be considered as part of the Offeror's technical evaluation.

3. **With regard to the updated print instructions on 2021 PBM Amendment 2, page 51, Part 5 Information for Offerors to Submit, please provide details on the differences between spiral and coil binding.**

A: Page 51, Part 5 Information for Offerors to Submit, Item b. should state the following:

- b. One (1) original and five (5) identical spiral bound paper copies of the Offeror's Technical Proposal. Please label copies, 1 of 5, 2 of 5, etc. (No **comb** binding and no three ring binders.)